Two million new cases of basal cell carcinoma are diagnosed in the U.S. every year.
The drug Vismodegib is the first to receive FDA approval to treat inoperable basal cell carcinoma; it will be marketed under the name Erivedge. It's a pill that's taken daily.
It is used to treat adult patients with advanced basal cell carcinoma, the most common type of skin cancer. It's intended for those wtih locally advanced basal cell cancer who are not candidates for surgery or radiation.
Clinical trial results showed visible tumor shrinkage and its approval by the FDA was fast-tracked.
For more health news, go to www.dailypress.com/health
Copyright © 2015, Los Angeles Times